New mRNA vaccine targets Epstein-Barr virus in early trial
NCT ID NCT07478952
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an mRNA vaccine called mRNA-1189 to see if it is safe and triggers an immune response against Epstein-Barr virus (EBV). EBV is a common virus that can cause mononucleosis and is linked to certain cancers. The study involves 120 healthy adults aged 18 to 30, who will receive the vaccine either under the skin or into a muscle. Researchers will monitor for side effects and measure antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mRNA-1189 vaccine
- What this could lead to
- If successful, this could lead to a vaccine that prevents Epstein-Barr virus infection, which is linked to mononucleosis and some cancers.
- What could go wrong
- This is an early Phase 1 trial with only 120 participants, so it's primarily checking safety and immune response. The vaccine may not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPSTEIN-BARR VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Doherty Clinical Trials
NOT_YET_RECRUITINGMelbourne, Victoria, VIC 3149, Australia
-
Nucleus Network
RECRUITINGMelbourne, Victoria, VIC 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.